Form 8-K - Current report:
SEC Accession No. 0001193125-25-122076
Filing Date
2025-05-19
Accepted
2025-05-19 06:21:08
Documents
15
Period of Report
2025-05-18
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d80735d8k.htm   iXBRL 8-K 43342
2 EX-99.1 d80735dex991.htm EX-99.1 32879
6 GRAPHIC g80735g23w83.jpg GRAPHIC 19710
7 GRAPHIC g80735g89s41.jpg GRAPHIC 11388
  Complete submission text file 0001193125-25-122076.txt   246768

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20250518.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20250518_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20250518_pre.xml EX-101.PRE 11259
17 EXTRACTED XBRL INSTANCE DOCUMENT d80735d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 25961436
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)